$RDI

Reading International (RDI) EVP exercises 8,768 RSUs, 4,160 shares withheld

Reading International's EVP and General Counsel, Sidney Craig Tompkins, exercised 8,768 Restricted Stock Units (RSUs) which converted into Class A Non-Voting Common shares. Concurrently, 4,160 shares were withheld to cover tax obligations related to this transaction. Following these conversions, Tompkins directly holds 152,419 Class A Non-Voting Common shares, and his RSU balance has been reduced to zero.

Original reporting
Published Apr 21, 2026, 10:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 21, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$RDI
Neutral
medium confidence
Mentioned
$RDI
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$RDINeutralLow
01

Why it matters

While such transactions can be positive signals, they should be interpreted cautiously and in conjunction with other fundamental and technical analysis.

02

Market read

The insider activity has limited immediate impact but may influence short-term trading sentiment.

03

What to watch

Broader market conditions and company fundamentals should be considered before making trading decisions

Timing: short-term

Background

Insider transactions, especially exercises of RSUs, can provide insights into insider confidence and potential future stock performance.

Company-level read

Ticker impact

$RDINeutralMedium confidence
Context

The insider transaction indicates increased insider ownership, which could suggest confidence in the company's prospects.

Expected impact

Potential slight upward pressure in the short term

Evidence & confidence

Insider transactions can be positive signals, but they are not definitive indicators of future performance. The neutral sentiment suggests limited immediate impact.

Market effects

Limited sector impact; insider transactions are company-specific

Minimal regional influence

Negligible

Counterpoint

Insider exercising RSUs could be for personal liquidity needs rather than positive company outlook, which might not translate into stock appreciation

Key entities

  • Reading International

    A company engaged in entertainment, media, and real estate.

Related articles

$RDIMed

Reading (RDI) Q2 2026 Earnings Call Transcript

Reading International (RDI) reported Q2 2026 revenue of $66.9M, up from prior periods, driven by strong cinema performance and real estate revenue growth. Net income rose to $2.3M, a 185% increase YoY, while EPS improved to $0.10. Adjusted EBITDA reached $11.3M, a 79% YoY increase. The company cited a strong movie slate and currency impacts as key factors.

$RDIMed

READING INTERNATIONAL INC (RDI): Results of Operations and Financial Condition

READING INTERNATIONAL INC (RDI) filed an SEC Form 8-K — Results of Operations and Financial Condition.  For more information, contact: Gilbert Avanes – EVP, CFO, and Treasurer (213) 235-22 40 Reading International Reports Second Quarter 2026 Results Earnings Call Webcast to Discuss Second Quarter Financial Results Scheduled to Post to Corporate Website on Tuesday , August 18 , 20

$AVAVLowAI 8/10

Jim Cramer Highlights AeroVironment’s (AVAV) Steep Competition

Jim Cramer advised against investing in AeroVironment (AVAV) despite a 40% stock drop, citing intense competition in the defense sector. The company reported record revenue of $1.98B for FY2026, up 141% YoY, driven by strong defense demand and a $464.8M U.S. Army contract. However, competition from firms like RTX and Lockheed Martin may pressure margins. Hedge fund interest grew, but short interest remains high at 9.55%.

$ANIPLow

ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board

ANI Pharmaceuticals (ANIP) appointed Henry Gosebruch to its board, replacing Muthusamy Shanmugam, who will remain in operational roles. Gosebruch has biotech leadership experience. The company, with a $1.6b market cap, develops and markets branded and generic drugs. Board changes may influence capital allocation and product mix.